Bausch + Lomb (NYSE:BLCO) Stock Rating Reaffirmed by Needham & Company LLC

Bausch + Lomb (NYSE:BLCO)‘s stock had its “hold” rating reissued by stock analysts at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports.

A number of other brokerages have also recently issued reports on BLCO. Wells Fargo & Company lifted their target price on Bausch + Lomb from $21.00 to $23.00 and gave the stock an “overweight” rating in a report on Thursday, February 22nd. Evercore decreased their target price on Bausch + Lomb from $17.00 to $16.50 and set an “in-line” rating on the stock in a report on Thursday, February 22nd. Barclays lifted their target price on Bausch + Lomb from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Royal Bank of Canada decreased their target price on Bausch + Lomb from $20.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday, April 22nd. Finally, Evercore ISI lifted their price target on Bausch + Lomb from $16.50 to $17.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.27.

Bausch + Lomb Stock Up 0.9 %

Shares of BLCO stock opened at $13.86 on Wednesday. Bausch + Lomb has a 1 year low of $13.16 and a 1 year high of $21.95. The stock has a market cap of $4.87 billion, a PE ratio of -18.73, a price-to-earnings-growth ratio of 1.40 and a beta of 0.47. The business’s fifty day moving average is $15.91 and its 200-day moving average is $15.64. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.09 and a current ratio of 1.74.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.06 billion. Bausch + Lomb had a negative net margin of 6.27% and a positive return on equity of 3.70%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. Equities analysts expect that Bausch + Lomb will post 0.65 earnings per share for the current fiscal year.

Institutional Trading of Bausch + Lomb

A number of institutional investors have recently bought and sold shares of BLCO. Black Swift Group LLC acquired a new stake in Bausch + Lomb during the third quarter valued at $170,000. Jump Financial LLC acquired a new stake in Bausch + Lomb during the third quarter valued at $255,000. Renaissance Capital LLC lifted its position in shares of Bausch + Lomb by 27.3% in the fourth quarter. Renaissance Capital LLC now owns 22,407 shares of the company’s stock worth $382,000 after buying an additional 4,801 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Bausch + Lomb in the third quarter worth about $466,000. Finally, Tectonic Advisors LLC lifted its position in shares of Bausch + Lomb by 4.7% in the third quarter. Tectonic Advisors LLC now owns 42,323 shares of the company’s stock worth $717,000 after buying an additional 1,907 shares during the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.